Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

NEXT STORY
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
PREV STORY
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Blood Plasma Derivatives Market Value Forecasted To Reach US$ 50.3 Billion By 2027 Covering COVID-19 Impact: Acumen Research And Consulting

author_avatar
NASDAQ Market News

Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in ...

author_avatar
NASDAQ Market News

Draganfly Selected to Globally Integrate Breakthrough Health Diagnosis Technology Immediately onto Autonomous Camera’s and Specialized Drones to Combat Coronavirus (COVID-19) and Future Health Emergencies

author_avatar
NASDAQ Market News